Objective： Triple-negative breast cancer（TNBC） is highly invasive and metastatic, which is in urgent need of transformative therapeutics. Tubeimu（TBM）, the rhizome of Bolbostemma paniculatum（Maxim.） Franquet, i...Objective： Triple-negative breast cancer（TNBC） is highly invasive and metastatic, which is in urgent need of transformative therapeutics. Tubeimu（TBM）, the rhizome of Bolbostemma paniculatum（Maxim.） Franquet, is one of the Chinese medicinal herbs used for breast diseases since the ancient times. The present study evaluated the efficacy, especially the anti-metastatic effects of the dichloromethane extract of Tubeimu（ETBM） on TNBC orthotopic mouse models and cell lines.Methods： We applied real-time imaging on florescent orthotopic TNBC mice model and tested cell migration and invasion abilities with MDA-MB-231 cell line. Digital gene expression sequencing was performed and Kyoto Encyclopedia of Genes and Genomes（KEGG） analysis applied to explore the pathways influenced by ETBM.Moreover, quantitative real-time polymerase chain reactions（q RT-PCR） and Western blot were delivered to confirm the gene expression changes.Results： ETBM exhibited noticeable control on tumor metastasis and growth of TNBC tumors with no obvious toxicity. In compliance with this, it also showed inhibition of cell migration and invasion in vitro. Its impact on the changed biological behavior in TNBC may be a result of decreased expression of integrin β1（ITGβ1）, integrin β8（ITGβ8） and Rho GTPase activating protein 5（ARHGAP5）, which disabled the focal adhesion pathway and caused change in cell morphology.Conclusions： This study reveals that ETBM has anti-metastatic effects on MDA-MB-231-GFP tumor and may lead to a new therapeutic agent for the integrative treatment of highly invasive TNBC.展开更多
BackgroundThe holistic view of the‘The unity of man and nature’promotes the development and application of traditional Chinese medicine(TCM).Despite the absence of modern pharmacological therapies with robust effica...BackgroundThe holistic view of the‘The unity of man and nature’promotes the development and application of traditional Chinese medicine(TCM).Despite the absence of modern pharmacological therapies with robust efficacy against coronavirus disease 2019(COVID-19),TCM has exhibited potential utility for treating the disease in clinical practice.MethodsA retrospective cohort study was conducted to investigate the therapeutic effect of TCM treatment intensity(TCMTI)in patients with mild COVID-19.A total of 6120 laboratory-confirmed patients with mild COVID-19 were recruited from temporary isolation facilities.The primary outcome measure was severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)ribonucleic acid conversion time.In addition,restricted cubic spline models were employed to elucidate nonlinear relationships.ResultsThe median age(range)of the study participants was 43.0(2.0–75.0)years,with a median hospitalization duration of 9.7(4.1–22.5)days.The median time for achieving SARS-CoV-2 ribonucleic acid negativity was 6.67 days.The restricted cubic spline models revealed a remarkable nonlinear association between TCMTI and the time-to-ribonucleic acid negativity.After adjusting for potential confounders,the high TCMTI group exhibited a markedly shorter median time to SARS-CoV-2 ribonucleic acid negativity and reduced hospitalization duration(P<0.001)than the low TCMTI group.Moreover,the mean time to achieve SARS-CoV-2 ribonucleic acid negativity was shortened by 1.909 days(P<0.001)in the high-TCMTI group compared to the low-TCMTI group.ConclusionThis study suggests that early initiation and intensified use of TCM may accelerate the time required to achieve SARS-CoV-2 ribonucleic acid negativity in patients with COVID-19,bearing considerable implications for public health.展开更多
Since the outbreak of coronavirus disease 2019(COVID-19),the author has been involved in the treatment of COVID-19 in the first line.It is found that some patients had a long viral nucleic acid negative time,and even ...Since the outbreak of coronavirus disease 2019(COVID-19),the author has been involved in the treatment of COVID-19 in the first line.It is found that some patients had a long viral nucleic acid negative time,and even the course of the disease lasted more than 40 days.After a thorough investigation of the root causes,it is found the four possible causes were:"Blood stasis syndrome"is difficult to remove;"Damp heat"sticky greasy;Stubborn basic diseases;weak constitution.All the patients treated with traditional Chinese medicine have turned negative,and now the typical cases were analyzed and summarized in order to provide reference for the traditional Chinese medicine treatment and scientific research of the patients with COVID-19 who were difficult to turn negative.展开更多
A 71-year-old woman suffered the pains from her finger joints, arms, shoulders and neck. The first prescription was theadd and subtract of Guizhishaoyaozhimu decoction, which could warm Yang via Fuzi （Radix Aconiti C...A 71-year-old woman suffered the pains from her finger joints, arms, shoulders and neck. The first prescription was theadd and subtract of Guizhishaoyaozhimu decoction, which could warm Yang via Fuzi （Radix Aconiti Carmichaeli）. Afterthree oral doses of medication, she felt sleepy with a blood pressure of 180/60 mmHg. The second prescription was theadd of Shengmai Powder which could nourish Yin. The next day, her blood pressure was reduced to 130/65 mmHg.展开更多
目的探讨中医特色护理在原发性高血压患者中的应用效果。方法选取2019年1月至2020年12月九江市中医医院收治的88例原发性高血压患者作为研究对象,按照随机数字表法分为对照组(44例)和观察组(44例)。两组患者均予以中医中药治疗,对照组...目的探讨中医特色护理在原发性高血压患者中的应用效果。方法选取2019年1月至2020年12月九江市中医医院收治的88例原发性高血压患者作为研究对象,按照随机数字表法分为对照组(44例)和观察组(44例)。两组患者均予以中医中药治疗,对照组采用常规护理,观察组采用中医特色护理,共护理4周。比较两组患者的血压水平[24 h收缩压(24 h SBP)、24 h舒张压(24 h DBP)]、中医症状评分、焦虑抑郁评分及生活质量。结果干预前,两组患者24 h SBP、24 h DBP及中医症状评分、焦虑抑郁评分比较,差异无统计学意义(P>0.05);干预后,两组患者24 h SBP、24 h DBP及中医症状评分、焦虑抑郁评分低于本组干预前,且观察组24 h SBP、24 h DBP及中医症状评分、焦虑抑郁评分低于对照组,差异有统计学意义(P<0.05)。干预前,两组患者生活质量评分比较,差异无统计学意义(P>0.05);干预后,两组患者生活质量评分高于本组干预前,且观察组生活质量评分高于对照组,差异有统计学意义(P<0.05)。结论中医特色护理干预有利于改善原发性高血压患者的血压水平及临床症状,提高生活质量。展开更多
目的:系统评价中医健康管理改善高血压前期人群健康结局的有效性。方法:计算机检索中国知网、万方数据库、维普数据库、中国生物医学文献数据库、Cochrane Library、PubMed、Web of Science、CINAHL中有关中医“治未病”理论的健康管理...目的:系统评价中医健康管理改善高血压前期人群健康结局的有效性。方法:计算机检索中国知网、万方数据库、维普数据库、中国生物医学文献数据库、Cochrane Library、PubMed、Web of Science、CINAHL中有关中医“治未病”理论的健康管理改善高血压前期人群健康结局的随机对照试验及类实验研究,检索时限为建库至2023年8月10日。由2名研究者进行文献筛选、质量评价及提取资料工作,采用RevMan 5.4及Stata 17软件进行分析。结果:共纳入9项随机对照试验、2项实验研究。干预组收缩压[MD=-5.08,95%CI(-6.44,-3.72),P<0.00001]、舒张压[MD=-3.78,95%CI(-5.13,-2.44),P<0.00001]、头痛发生率[OR=0.35,95%CI(0.25,0.49),P<0.00001]、眩晕发生率[OR=-0.15,95%CI(-0.21,-0.08),P<0.00001]、全血黏度[MD=-1.05,95%CI(-1.14,-0.96),P<0.00001]、甘油三酯[MD=-0.67,95%CI(-0.75,-0.59),P<0.00001]均低于对照组,差异均有统计学意义。结论:基于中医“治未病”理论的健康管理能有效改善高血压前期人群的健康结局,但其模式仍需进一步规范。展开更多
目的探究耳穴压丸对环状混合痔切除术后患者肛门疼痛的缓解作用。方法将60例环状混合痔术后患者随机分为对照组30例和研究组30例。其中,对照组常规予以氯诺昔康静脉滴注止痛治疗,研究组在对照组的基础上增加神门、直肠、大肠、交感耳穴...目的探究耳穴压丸对环状混合痔切除术后患者肛门疼痛的缓解作用。方法将60例环状混合痔术后患者随机分为对照组30例和研究组30例。其中,对照组常规予以氯诺昔康静脉滴注止痛治疗,研究组在对照组的基础上增加神门、直肠、大肠、交感耳穴压丸治疗。对比术后1、3、7 d 2组患者疼痛视觉评分、氯诺昔康的追加剂量、排便时间、不良反应发生情况。结果2组患者术后疼痛均可得到有效缓解。研究组患者肛门疼痛评分高于对照组,但追加氯诺昔康剂量少于对照组,药物不良反应较少。研究组患者均次排便时间明显小于对照组,差异有统计学意义(P<0.05)。结论耳穴压丸能够缩短混合痔术后患者排便时间,有效缓解环状混合痔切除术后肛门疼痛,且不良反应较少,临床可用于辅助缓解患者术后疼痛。展开更多
基金supported by National Natural Science Foundation of China Grant (No. 81303129)Beijing University of Chinese Medicine Grant (Project ID: 2016-jxs-548)
文摘Objective： Triple-negative breast cancer（TNBC） is highly invasive and metastatic, which is in urgent need of transformative therapeutics. Tubeimu（TBM）, the rhizome of Bolbostemma paniculatum（Maxim.） Franquet, is one of the Chinese medicinal herbs used for breast diseases since the ancient times. The present study evaluated the efficacy, especially the anti-metastatic effects of the dichloromethane extract of Tubeimu（ETBM） on TNBC orthotopic mouse models and cell lines.Methods： We applied real-time imaging on florescent orthotopic TNBC mice model and tested cell migration and invasion abilities with MDA-MB-231 cell line. Digital gene expression sequencing was performed and Kyoto Encyclopedia of Genes and Genomes（KEGG） analysis applied to explore the pathways influenced by ETBM.Moreover, quantitative real-time polymerase chain reactions（q RT-PCR） and Western blot were delivered to confirm the gene expression changes.Results： ETBM exhibited noticeable control on tumor metastasis and growth of TNBC tumors with no obvious toxicity. In compliance with this, it also showed inhibition of cell migration and invasion in vitro. Its impact on the changed biological behavior in TNBC may be a result of decreased expression of integrin β1（ITGβ1）, integrin β8（ITGβ8） and Rho GTPase activating protein 5（ARHGAP5）, which disabled the focal adhesion pathway and caused change in cell morphology.Conclusions： This study reveals that ETBM has anti-metastatic effects on MDA-MB-231-GFP tumor and may lead to a new therapeutic agent for the integrative treatment of highly invasive TNBC.
基金supported by the Project on Prevention and Treatment of COVID-19 with Traditional Chinese Medicine[grant number XGYJKY2022-09]the Intervention Effect on COVID-19 in High-Risk Groups[grant number 2022ZYLCYJ05-10]+2 种基金the Three-Year Action Plan for Promoting Clinical Skills and Innovation Ability of Municipal Hospitals[grant number SHDC2022CRS039]Shanghai Natural Science Foundation[grant numbers 22ZR1462100,23ZR1464000,23ZR1463900]the talent fund of Longhua Hospital[grant number LH001.007].
文摘BackgroundThe holistic view of the‘The unity of man and nature’promotes the development and application of traditional Chinese medicine(TCM).Despite the absence of modern pharmacological therapies with robust efficacy against coronavirus disease 2019(COVID-19),TCM has exhibited potential utility for treating the disease in clinical practice.MethodsA retrospective cohort study was conducted to investigate the therapeutic effect of TCM treatment intensity(TCMTI)in patients with mild COVID-19.A total of 6120 laboratory-confirmed patients with mild COVID-19 were recruited from temporary isolation facilities.The primary outcome measure was severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)ribonucleic acid conversion time.In addition,restricted cubic spline models were employed to elucidate nonlinear relationships.ResultsThe median age(range)of the study participants was 43.0(2.0–75.0)years,with a median hospitalization duration of 9.7(4.1–22.5)days.The median time for achieving SARS-CoV-2 ribonucleic acid negativity was 6.67 days.The restricted cubic spline models revealed a remarkable nonlinear association between TCMTI and the time-to-ribonucleic acid negativity.After adjusting for potential confounders,the high TCMTI group exhibited a markedly shorter median time to SARS-CoV-2 ribonucleic acid negativity and reduced hospitalization duration(P<0.001)than the low TCMTI group.Moreover,the mean time to achieve SARS-CoV-2 ribonucleic acid negativity was shortened by 1.909 days(P<0.001)in the high-TCMTI group compared to the low-TCMTI group.ConclusionThis study suggests that early initiation and intensified use of TCM may accelerate the time required to achieve SARS-CoV-2 ribonucleic acid negativity in patients with COVID-19,bearing considerable implications for public health.
基金Science and Technology Research Project of Jiangxi Provincial Department of Science and Technology(No.S2020ZPYFG0006)Training Project of National Traditional Chinese Medicine Innovative Key Talents National Chinese Medicine(2019)(No.128)
文摘Since the outbreak of coronavirus disease 2019(COVID-19),the author has been involved in the treatment of COVID-19 in the first line.It is found that some patients had a long viral nucleic acid negative time,and even the course of the disease lasted more than 40 days.After a thorough investigation of the root causes,it is found the four possible causes were:"Blood stasis syndrome"is difficult to remove;"Damp heat"sticky greasy;Stubborn basic diseases;weak constitution.All the patients treated with traditional Chinese medicine have turned negative,and now the typical cases were analyzed and summarized in order to provide reference for the traditional Chinese medicine treatment and scientific research of the patients with COVID-19 who were difficult to turn negative.
文摘A 71-year-old woman suffered the pains from her finger joints, arms, shoulders and neck. The first prescription was theadd and subtract of Guizhishaoyaozhimu decoction, which could warm Yang via Fuzi （Radix Aconiti Carmichaeli）. Afterthree oral doses of medication, she felt sleepy with a blood pressure of 180/60 mmHg. The second prescription was theadd of Shengmai Powder which could nourish Yin. The next day, her blood pressure was reduced to 130/65 mmHg.
文摘目的探讨中医特色护理在原发性高血压患者中的应用效果。方法选取2019年1月至2020年12月九江市中医医院收治的88例原发性高血压患者作为研究对象,按照随机数字表法分为对照组(44例)和观察组(44例)。两组患者均予以中医中药治疗,对照组采用常规护理,观察组采用中医特色护理,共护理4周。比较两组患者的血压水平[24 h收缩压(24 h SBP)、24 h舒张压(24 h DBP)]、中医症状评分、焦虑抑郁评分及生活质量。结果干预前,两组患者24 h SBP、24 h DBP及中医症状评分、焦虑抑郁评分比较,差异无统计学意义(P>0.05);干预后,两组患者24 h SBP、24 h DBP及中医症状评分、焦虑抑郁评分低于本组干预前,且观察组24 h SBP、24 h DBP及中医症状评分、焦虑抑郁评分低于对照组,差异有统计学意义(P<0.05)。干预前,两组患者生活质量评分比较,差异无统计学意义(P>0.05);干预后,两组患者生活质量评分高于本组干预前,且观察组生活质量评分高于对照组,差异有统计学意义(P<0.05)。结论中医特色护理干预有利于改善原发性高血压患者的血压水平及临床症状,提高生活质量。
文摘目的探究耳穴压丸对环状混合痔切除术后患者肛门疼痛的缓解作用。方法将60例环状混合痔术后患者随机分为对照组30例和研究组30例。其中,对照组常规予以氯诺昔康静脉滴注止痛治疗,研究组在对照组的基础上增加神门、直肠、大肠、交感耳穴压丸治疗。对比术后1、3、7 d 2组患者疼痛视觉评分、氯诺昔康的追加剂量、排便时间、不良反应发生情况。结果2组患者术后疼痛均可得到有效缓解。研究组患者肛门疼痛评分高于对照组,但追加氯诺昔康剂量少于对照组,药物不良反应较少。研究组患者均次排便时间明显小于对照组,差异有统计学意义(P<0.05)。结论耳穴压丸能够缩短混合痔术后患者排便时间,有效缓解环状混合痔切除术后肛门疼痛,且不良反应较少,临床可用于辅助缓解患者术后疼痛。
